Quantcast
Home > Quotes > PFNX

Pfenex Inc. Common Stock (PFNX) Quote & Summary Data

PFNX 
$5.05
*  
0.30
5.61%
Get PFNX Alerts
*Delayed - data as of Jul. 16, 2018 14:12 ET  -  Find a broker to begin trading PFNX now
Exchange:AMEX
Industry: Health Care
Community Rating:
View:    PFNX Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
8
Today's High / Low
$ 5.61 / $ 5
Share Volume
153,759
90 Day Avg. Daily Volume
199,767
Previous Close
$ 5.35
52 Week High / Low
$ 8.419 / $ 2.07
Market Cap
119,097,104
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.61

Intraday Chart

Shares Traded

Share Volume:
153,759
90 Day Avg. Daily Volume:
199,767

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.13

Trading Range

The current last sale of $5.05 is 143.96% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.61 $ 8.419
 Low: $ 5 $ 2.07

Company Description (as filed with the SEC)

We are a clinical-stage development and licensing biotechnology company focused on leveraging our Pfenex Expression Technology® to improve protein therapies for unmet patient needs. Using the patented Pfenex Expression Technology platform, we have created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Our lead product candidates are PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis, and our novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the U.S. government. In addition, we are developing hematology/oncology products in collaboration with Jazz Pharmaceuticals. Furthermore, our pipeline includes biosimilar candidates to Lucentis® and Neulasta®.  ... More ...  

Risk Grade

Where does PFNX fit in the risk graph?


Risk Grade Scale

Consensus Recommendation

Analyst Info